A combination of constituents for oral administration by women with polycystic ovarian syndrome includes .alpha.-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacture is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid. A combination of constituents for administration by either men or women to encourage increase in brain insulin levels and/or brain insulin receptor functionality also includes .alpha.-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10.